|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:GLB1-ROCK2 (FusionGDB2 ID:33097) |
Fusion Gene Summary for GLB1-ROCK2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: GLB1-ROCK2 | Fusion gene ID: 33097 | Hgene | Tgene | Gene symbol | GLB1 | ROCK2 | Gene ID | 2720 | 9475 |
| Gene name | galactosidase beta 1 | Rho associated coiled-coil containing protein kinase 2 | |
| Synonyms | EBP|ELNR1|MPS4B | ROCK-II | |
| Cytomap | 3p22.3 | 2p25.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | beta-galactosidaseacid beta-galactosidaseelastin binding proteinelastin receptor 1, 67kDalactase | rho-associated protein kinase 2p164 ROCK-2rho-associated, coiled-coil-containing protein kinase II | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | P16278 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000307363, ENST00000399402, ENST00000445488, ENST00000307377, ENST00000497796, | ENST00000315872, ENST00000462366, ENST00000401753, | |
| Fusion gene scores | * DoF score | 9 X 9 X 7=567 | 3 X 3 X 2=18 |
| # samples | 9 | 3 | |
| ** MAII score | log2(9/567*10)=-2.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: GLB1 [Title/Abstract] AND ROCK2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | GLB1(33093249)-ROCK2(11341269), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | GLB1-ROCK2 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. GLB1-ROCK2 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF. GLB1-ROCK2 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | GLB1 | GO:0044262 | cellular carbohydrate metabolic process | 11927518 |
| Tgene | ROCK2 | GO:0006468 | protein phosphorylation | 18559669 |
| Fusion gene breakpoints across GLB1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ROCK2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-HU-A4GF | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
Top |
Fusion Gene ORF analysis for GLB1-ROCK2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000307363 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000307363 | ENST00000462366 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000307363 | ENST00000401753 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| In-frame | ENST00000399402 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000399402 | ENST00000462366 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000399402 | ENST00000401753 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| Frame-shift | ENST00000445488 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000445488 | ENST00000462366 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000445488 | ENST00000401753 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| Frame-shift | ENST00000307377 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000307377 | ENST00000462366 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| 5CDS-intron | ENST00000307377 | ENST00000401753 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| intron-3CDS | ENST00000497796 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| intron-intron | ENST00000497796 | ENST00000462366 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| intron-intron | ENST00000497796 | ENST00000401753 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000399402 | GLB1 | chr3 | 33093249 | - | ENST00000315872 | ROCK2 | chr2 | 11341269 | - | 6117 | 997 | 989 | 2440 | 483 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000399402 | ENST00000315872 | GLB1 | chr3 | 33093249 | - | ROCK2 | chr2 | 11341269 | - | 0.000378188 | 0.99962175 |
Top |
Fusion Genomic Features for GLB1-ROCK2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for GLB1-ROCK2 |
| Go to FGviewer for the breakpoints of chr3:33093249-chr2:11341269 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| GLB1 | . |
| FUNCTION: [Isoform 1]: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans. {ECO:0000269|PubMed:15714521, ECO:0000269|PubMed:19472408, ECO:0000269|PubMed:2511208, ECO:0000269|PubMed:25936995, ECO:0000269|PubMed:8200356}.; FUNCTION: [Isoform 2]: Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cancer cell types. In elastin producing cells, associates with tropoelastin intracellularly and functions as a recycling molecular chaperone which facilitates the secretions of tropoelastin and its assembly into elastic fibers. {ECO:0000269|PubMed:10841810, ECO:0000269|PubMed:8922281}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 1053_1131 | 907.6666666666666 | 1389.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 1150_1349 | 907.6666666666666 | 1389.0 | Domain | PH | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 979_1047 | 907.6666666666666 | 1389.0 | Region | RHOA binding | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 1260_1315 | 907.6666666666666 | 1389.0 | Zinc finger | Phorbol-ester/DAG-type |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 429_1024 | 907.6666666666666 | 1389.0 | Coiled coil | Ontology_term=ECO:0000255 | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 357_425 | 907.6666666666666 | 1389.0 | Domain | AGC-kinase C-terminal | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 497_573 | 907.6666666666666 | 1389.0 | Domain | REM-1 | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 92_354 | 907.6666666666666 | 1389.0 | Domain | Protein kinase | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 98_106 | 907.6666666666666 | 1389.0 | Nucleotide binding | ATP |
Top |
Fusion Gene Sequence for GLB1-ROCK2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000399402_ENST00000315872_TCGA-HU-A4GF_GLB1_chr3_33093249_-_ROCK2_chr2_11341269_length(transcript)=6117nt_BP=997nt GGGCGGGCCGGGCGGGGCGCGCGTCCTTCCAGGCAGCTCGGTCGCTTGTGCGTTCCGCTCCGGCCGCCCTTTGCGCTTGGATCCACTTCC CCATCTGTAACGAGGTGTTGAGACGAGAATGCCACCCAGAGGATGTTTGAAATTGACTATAGCCGGGACTCCTTCCTCAAGGATGGCCAG CCATTTCGCTACATCTCAGGAAGCATTCACTACTCCCGTGTGCCCCGCTTCTACTGGAAGGACCGGCTGCTGAAGATGAAGATGGCTGGG CTGAACGCCATCCAGACGTATGTGCCCTGGAACTTTCATGAGCCCTGGCCAGGACAGTACCAGTTTTCTGAGGACCATGATGTGGAATAT TTTCTTCGGCTGGCTCATGAGCTGGGACTGCTGGTTATCCTGAGGCCCGGGCCCTACATCTGTGCAGAGTGGGAAATGGGAGGATTACCT GCTTGGCTGCTAGAGAAAGAGTCTATTCTTCTCCGCTCCTCCGACCCAGATTACCTGGCAGCTGTGGACAAGTGGTTGGGAGTCCTTCTG CCCAAGATGAAGCCTCTCCTCTATCAGAATGGAGGGCCAGTTATAACAGTGCAGGTTGAAAATGAATATGGCAGCTACTTTGCCTGTGAT TTTGACTACCTGCGCTTCCTGCAGAAGCGCTTTCGCCACCATCTGGGGGATGATGTGGTTCTGTTTACCACTGATGGAGCACATAAAACA TTCCTGAAATGTGGGGCCCTGCAGGGCCTCTACACCACGGTGGACTTTGGAACAGGCAGCAACATCACAGATGCTTTCCTAAGCCAGAGG AAGTGTGAGCCCAAAGGACCCTTGATCAATTCTGAATTCTATACTGGCTGGCTAGATCACTGGGGCCAACCTCACTCCACAATCAAGACC GAAGCAGTGGCTTCCTCCCTCTATGATATACTTGCCCGTGGGGCGAGTGTGAACTTGTACATGTTTATAGGTGGGACCAATTTTGCCTAT TGGAATGGGACTCTTTGGCTGCCCAACTGGAGATCACCTTGACCAAAGCAGATTCTGAGCAACTGGCTCGTTCAATTGCTGAAGAACAAT ATTCTGATTTGGAAAAAGAGAAGATCATGAAAGAGCTGGAGATCAAAGAGATGATGGCTAGACACAAACAGGAACTTACGGAAAAAGATG CTACAATTGCTTCTCTTGAGGAAACTAATAGGACACTAACTAGTGATGTTGCCAATCTTGCAAATGAGAAAGAAGAATTAAATAACAAAT TGAAAGATGTTCAAGAGCAACTGTCAAGATTGAAAGATGAAGAAATAAGCGCAGCAGCTATTAAAGCACAGTTTGAGAAGCAGCTATTAA CAGAAAGAACACTCAAAACTCAAGCTGTGAATAAGTTGGCTGAGATCATGAATCGAAAAGAACCTGTCAAGCGTGGTAATGACACAGATG TGCGGAGAAAAGAGAAGGAGAATAGAAAGCTACATATGGAGCTTAAATCTGAACGTGAGAAATTGACCCAGCAGATGATCAAGTATCAGA AAGAACTGAATGAAATGCAGGCACAAATAGCTGAAGAGAGCCAGATTCGAATTGAACTGCAGATGACATTGGACAGTAAAGACAGTGACA TTGAGCAGCTGCGGTCACAACTCCAAGCCTTGCATATTGGTCTGGATAGTTCCAGTATAGGCAGTGGACCAGGGGATGCTGAGGCAGATG ATGGGTTTCCAGAATCAAGATTAGAAGGATGGCTTTCATTGCCTGTACGAAACAACACTAAGAAATTTGGATGGGTTAAAAAGTATGTGA TTGTAAGCAGTAAGAAGATTCTTTTCTATGACAGTGAACAAGATAAAGAACAATCCAATCCTTACATGGTTTTAGATATAGACAAGTTAT TTCATGTCCGACCAGTTACACAGACAGATGTGTATAGAGCAGATGCTAAAGAAATTCCAAGGATATTCCAGATTCTGTATGCCAATGAAG GAGAAAGTAAGAAGGAACAAGAATTTCCAGTGGAGCCAGTTGGAGAAAAATCTAATTATATTTGCCACAAGGGACATGAGTTTATTCCTA CTCTTTATCATTTCCCAACCAACTGTGAGGCTTGTATGAAGCCCCTGTGGCACATGTTTAAGCCTCCTCCTGCTTTGGAGTGCCGCCGTT GCCATATTAAGTGTCATAAAGATCATATGGACAAAAAGGAGGAGATTATAGCACCTTGCAAAGTATATTATGATATTTCAACGGCAAAGA ATCTGTTATTACTAGCAAATTCTACAGAAGAGCAGCAGAAGTGGGTTAGTCGGTTGGTGAAAAAGATACCTAAAAAGCCCCCAGCTCCAG ACCCTTTTGCCCGATCATCTCCTAGAACTTCAATGAAGATACAGCAAAACCAGTCTATTAGACGGCCAAGTCGACAGCTTGCCCCAAACA AACCTAGCTAACTGCCTTCTATGAAAGCAGTCATTATTCAAGGTGATCGTATTCTTCCAGTGAAAACAAGACTGAAATATGATGGCCCAA AATTTATTAAAAAGCTATATTTTCCTGAGAGACTGATACATACACTCATACATATATGTGTTCCCCTTTTCCCTGTAATATAAATTACAA ATCTGGGCTCCTTTGAAGCAACAGGTTGAACCAACAATGATTGGTTGATAGACTAAGGATATATGCAACTCTTCCAGACTTTTCCATAAA GCTCTCTCGGCAGTCGCTCACACTACAATGCACACAAGGATTGAGAAGAGTTAAAGGCTAAAGAAAACATCTTTTCTAGCTTCAACAGAG AGGTTTCACCAGCACATTTACCAGAAGAATCTGGGAATGGATTCCACTACAGTGATATTGACTGCATCTTTAAGAAGTGACCATTATACT GTGTATATATATATAAACACACACACATATATATATATATATATAGTACTCTAATACTGCAAGAAGGTTTTTTAAACTTCCCACTTTATT TTTTATACACATTAATCAGATATCATTACTTGCTGCAGTTGCAACTATGCACTTGTATAAAGCCATAATGTTGGAGTTTATATCACTCAT TCCTGTGTACCTGATGGAAGTTGCATGTTCATGTTTAAGCAGTTACTGTAACAAGAAGTTTAAAGTTAATTATATCAGTTTCCTAATGCT TCATGATAGGCAACTTTACCCATTTTGAATGCCTTAATTTAATTTTTTTCAAAGTCTCAGCCCTGTCTGTATTAAAAAACAAAAAAAGCG TTTACCAGCTCTTAGGATGTAAACTAGCTTTGTGGAAGATAAATCGTGCACTATTTTTACACATAAATAGTTATATCAATGTCAGCCTAT TTTGATTAACAAATGTTTTTAAAGTATTATTGGTTATAGAAACAATAATGGATGGTGTTGGAACTAATATATCCTTGATGTCTGTCTATT ATTCATTCAACTCTTTTTACAGACCTCAGTATTAGTCTGTGACTACAAAATATTTTATTTGCTTTAAATTTGCTGGCTACCCTAGATGTG TTTTTATTCCTGGTAAAGACATTTGTGATTACATTTTCACACTTAAGATTCAAAATTTTTCCCAAATATAAAGAAAACTAAGACAGACTG TAGATGCATTTTAAATATTTAAATATGATCCTCAGACATGCAGCTGTGTGTGGCAGTATTTTAGTACCGGGTTAAGAAAACTGGCAACTG GGAAGAAGTGGCCTCAAAGGCACTTAATTTGATTTTTATTTTTTAAATGCTGTCAAAGTTACAGTTTACGCAGGACATTCTTGCCGTATT CTCATGATCCCAGATAAGTGTGTGTTTTATACTGCAACAATATGCAGCAATGGTAAGCGTAAAGTTTTTTTTTTGTTTTTGTTTTTTTTT ATATTATGAAGTCTTTTAACAGTCTCTCTTTATATAAATACACAGAGTTTGGTATGATATTTAAATACATCATCTGGCCAGGCATGGTGG CTTACGCCTGTAATCCTAGCACTTTGGGAGGCCAAGACGGGCGGATCACCTGAGGTGAGGAGTTCAAGACCAGCCTGCCCAACATAGTGA AACTCCGTCTCTACCAATATACAAAAATTAGCCGGGCATGATGGTGGTGGCCTGTAATCCCAGCTACTTGGGAGGCTGAGACAGGAGAAT CGCTTGAACCCAGGAGACGGTGGTTGCAGTGAGCGAAGATCGAGCCACTGCACTCCAGCCTGGGCAGCTGAACAAGACTCCGTCTCAAAA AAAAAAAAAAAAAAAAGTCATCTAATATTTCGATGAAGGAAATAGACATTTTTCATTGATTCCCTCTGATGTCAGTTAGAGATATTTAAA AAGTTAGATCCCCATAATAGATACTATTGTGGAAACTGAAGAGTAGCTACTGGCCTACTGATAGACTGAAACTGGTTTTGTTATTCTTAA CGTTCTCCAGTCTGCACTCTGCTGTGCTGTCTGTGCTCAGACTAGACGTGCATGCCGTTTCCTTTGCAGGTGTGTTCTGCAGCTCTGGTT TTGGGGGATAGCTCTTTTTTAAGTAAGATTAAAAAATGAAAAATATATAAATTTATATAGAATAAATATTTCCATTCATTAGAGTTGTTA AAAGGAGACTGAATTAATATTTTATATAAAGATTTTGTTACATTATGGGAGGTTCTATCCTATTCTGAATTGGAGAGTATATATATATAT ATATATATATATATATTTTTAATAAACTTTATTAAGGTGAAATAATTTCAAGTTTACATATGAGTAACTGAAATATTTGAGTAAAAAAGG CAAAAGTTTAAATTTGGAATGCTGTATATATTAGAGAATATGGGGAATCATGGTGTGACCAACTGTACAAGGAAGATTCATATGAAGGTC TTAGGGGAAAAAGATAATTCTGAAGGGTGAAAAAAAAATCTCTCCCATGGAGATTCTTCACATTATATGGTTTGACATAAGGGTTTATAA GGTTGTTTGTCCAACTAATGAAAATGCGCTTAATAAAAAATTCTGACCTTGGGTAAGAATTCGCTTTTTACCGCATTGCCGCTTTCATGT ACATACATGAGTGCATGCACCTATCAATGTGTTTTCTTCCCAACACTTATTAAATATAAAACAACCTGATTTTGTGCTCGTTTCTCGTTT TTCTTGAGGCCCTGAAGCTTCCAAGATAAATATAAGACTAAAATTTGCTTGTTCCTTCACACCTGATTTCTCCTAGAACCATAAATACCT CCTATGGGGAACTAAGAAATCATGAATACTGGGATTTTCTTATTGGATTTTTTACTTTTGTTTTGTGGGGATAACGAGACAGAAGTGAAA GGAAAACTGGTGCCGGTATTACTGTTGAAATTAATGTACAGTGAATGTTTTTAAAGTATTAATTTTAAAAAACCATGTTCTCTAGAAACA AGTTTTAAAAATCTATATGAAAGTTTTAAAATGTTCCAGCTAACTAATGGATAAGCATACCAGTAAAGCCAAAGTAAAGGTTAGTGCCTT TAAAACTAACCTGTGTTAGAGTTACATGAATCTGGCTCTAAAGTATCTATTTTGCATCCATTTATATATAGATCTTAAACAGAAATACTC TAGGTTGCCACACCACAGTTTTAAGAAGTTATGCTGCTGCTGTTACTCTCTTCTAGGATTCTGGTGGTAAAGTAGAGAAACTCGGACACT ATATTAACCTTACTGAAACATGCTTTAAATCGTGTCTAAAATCTGATTTGAGCAAGTCACTGCCGAGCTTCTGAGTCTGCATTGACACTG CTACTGACTCACCTCTCCTTCCCTGGAATAAGGCTTCAGCTTCCCTATGCTGTGAAGACACCATTTGTAAGCACTTTGAACATAAGCACT GTGTGACAGCGCTGGATATCATGCTTGGGGGGGGGCCTCTCCCTGACTCCCATCCCCATAATAATGAGTTTTGTTTGGAATTGTAATAAG TAATGAACTGCATGGTTTAGAAAATTATAAATATTTGATCAGCTGTCCTCTCTGAAAAAAATTGCACCCCTTTTTCTTTTTTAAAATTTT >In-frame_ENST00000399402_ENST00000315872_TCGA-HU-A4GF_GLB1_chr3_33093249_-_ROCK2_chr2_11341269_length(amino acids)=483AA_start in transcript=989_stop in transcript=2440 MEWDSLAAQLEITLTKADSEQLARSIAEEQYSDLEKEKIMKELEIKEMMARHKQELTEKDATIASLEETNRTLTSDVANLANEKEELNNK LKDVQEQLSRLKDEEISAAAIKAQFEKQLLTERTLKTQAVNKLAEIMNRKEPVKRGNDTDVRRKEKENRKLHMELKSEREKLTQQMIKYQ KELNEMQAQIAEESQIRIELQMTLDSKDSDIEQLRSQLQALHIGLDSSSIGSGPGDAEADDGFPESRLEGWLSLPVRNNTKKFGWVKKYV IVSSKKILFYDSEQDKEQSNPYMVLDIDKLFHVRPVTQTDVYRADAKEIPRIFQILYANEGESKKEQEFPVEPVGEKSNYICHKGHEFIP TLYHFPTNCEACMKPLWHMFKPPPALECRRCHIKCHKDHMDKKEEIIAPCKVYYDISTAKNLLLLANSTEEQQKWVSRLVKKIPKKPPAP -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for GLB1-ROCK2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 373_420 | 907.6666666666666 | 1389.0 | NPM1 | |
| Tgene | ROCK2 | chr3:33093249 | chr2:11341269 | ENST00000315872 | 21 | 33 | 363_784 | 907.6666666666666 | 1389.0 | PPP1R12A |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for GLB1-ROCK2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | GLB1 | P16278 | DB04465 | Lactose | Small molecule | Approved|Experimental|Investigational | |
| Hgene | GLB1 | P16278 | DB04465 | Lactose | Small molecule | Approved|Experimental|Investigational |
Top |
Related Diseases for GLB1-ROCK2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | GLB1 | C0268271 | Gangliosidosis, Generalized GM1, Type 1 (disorder) | 21 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | GLB1 | C0268272 | Gangliosidosis, Generalized GM1, Type 2 | 14 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | GLB1 | C0268273 | Gangliosidosis, Generalized GM1, Type 3 | 13 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | GLB1 | C0086652 | Mucopolysaccharidosis type IVB | 12 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | GLB1 | C0026707 | Mucopolysaccharidosis IV | 4 | CTD_human;GENOMICS_ENGLAND |
| Hgene | GLB1 | C0086651 | Mucopolysaccharidosis, MPS-IV-A | 2 | CTD_human |
| Hgene | GLB1 | C3179194 | GALNS Deficiency | 2 | CTD_human |
| Hgene | GLB1 | C0005941 | Bone Diseases, Developmental | 1 | CTD_human |
| Hgene | GLB1 | C0010038 | Corneal Opacity | 1 | CTD_human |
| Hgene | GLB1 | C0011615 | Dermatitis, Atopic | 1 | CTD_human |
| Hgene | GLB1 | C0011616 | Contact Dermatitis | 1 | CTD_human |
| Hgene | GLB1 | C0013366 | Dyschondroplasias | 1 | CTD_human |
| Hgene | GLB1 | C0025237 | Melnick-Needles Syndrome | 1 | CTD_human |
| Hgene | GLB1 | C0026760 | Multiple Epiphyseal Dysplasia | 1 | CTD_human |
| Hgene | GLB1 | C0029422 | Osteochondrodysplasias | 1 | CTD_human |
| Hgene | GLB1 | C0036391 | Schwartz-Jampel Syndrome | 1 | CTD_human |
| Hgene | GLB1 | C0036572 | Seizures | 1 | GENOMICS_ENGLAND |
| Hgene | GLB1 | C0038015 | Spondyloepiphyseal Dysplasia | 1 | CTD_human |
| Hgene | GLB1 | C0086196 | Eczema, Infantile | 1 | CTD_human |
| Hgene | GLB1 | C0162351 | Contact hypersensitivity | 1 | CTD_human |
| Hgene | GLB1 | C0432272 | Van Buchem disease | 1 | CTD_human |
| Hgene | GLB1 | C3541456 | Spondyloepiphyseal Dysplasia Tarda, X-Linked | 1 | CTD_human |
| Hgene | GLB1 | C4551479 | Schwartz-Jampel Syndrome, Type 1 | 1 | CTD_human |
| Tgene | ROCK2 | C0018800 | Cardiomegaly | 1 | CTD_human |
| Tgene | ROCK2 | C0018801 | Heart failure | 1 | CTD_human |
| Tgene | ROCK2 | C0018802 | Congestive heart failure | 1 | CTD_human |
| Tgene | ROCK2 | C0023212 | Left-Sided Heart Failure | 1 | CTD_human |
| Tgene | ROCK2 | C0235527 | Heart Failure, Right-Sided | 1 | CTD_human |
| Tgene | ROCK2 | C0600519 | Ventricular Remodeling | 1 | CTD_human |
| Tgene | ROCK2 | C0600520 | Left Ventricle Remodeling | 1 | CTD_human |
| Tgene | ROCK2 | C1383860 | Cardiac Hypertrophy | 1 | CTD_human |
| Tgene | ROCK2 | C1959583 | Myocardial Failure | 1 | CTD_human |
| Tgene | ROCK2 | C1961112 | Heart Decompensation | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies